| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ENT1 |
| WB Predicted band size | 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SLC29A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC29A1抗体的3篇参考文献摘要简述：
---
1. **标题**：*"Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in pancreatic adenocarcinoma"*
**作者**：Farrell JJ 等
**摘要**：通过免疫组化(使用SLC29A1抗体)分析胰腺癌组织中hENT1蛋白表达，发现低表达患者对吉西他滨治疗反应差，生存期缩短，提示其作为化疗疗效预测标志物的潜力。
2. **标题**：*"Immunohistochemical detection of ENT1 in formalin-fixed paraffin-embedded cancer tissues"*
**作者**：Spratlin J 等
**摘要**：验证了一种SLC29A1抗体在福尔马林固定石蜡包埋组织中的特异性，证实其在多种癌症(如乳腺癌、结直肠癌)中检测hENT1膜定位的可靠性，为临床样本分析提供方法学支持。
3. **标题**：*"Single nucleotide polymorphisms of the human equilibrative nucleoside transporter 1 gene and response to 5-fluorouracil in colon cancer cell lines"*
**作者**：Gray JH 等
**摘要**：利用SLC29A1抗体通过Western blot检测不同SNP变异结肠癌细胞系的hENT1蛋白水平，发现特定基因型导致蛋白表达差异，影响5-氟尿嘧啶的细胞毒性效应。
---
以上研究均通过SLC29A1抗体进行蛋白水平的功能或临床相关性分析，涵盖肿瘤预后、检测方法验证及药物反应机制等领域。
The SLC29A1 antibody is a key tool for studying the solute carrier family 29 member 1 (SLC29A1), a nucleoside transporter protein also known as equilibrative nucleoside transporter 1 (ENT1). SLC29A1 facilitates the bidirectional transport of nucleosides (e.g., adenosine) and nucleobases across cell membranes, playing a critical role in cellular nucleotide homeostasis, signaling, and drug uptake. It is widely expressed in tissues such as the liver, kidney, brain, and immune cells, and is implicated in physiological processes like cardiovascular regulation, immune response, and cancer progression. Dysregulation of SLC29A1 is linked to chemotherapy resistance, neurological disorders, and inflammatory diseases.
SLC29A1 antibodies are designed to detect endogenous SLC29A1 proteins in applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. These antibodies typically target specific epitopes, such as the N- or C-terminal regions, and are validated for specificity using knockdown/knockout controls. Researchers use them to investigate SLC29A1 expression patterns, subcellular localization (primarily plasma and mitochondrial membranes), and regulatory mechanisms under pathological conditions. Commercial antibodies may vary in host species (e.g., rabbit, mouse), clonality (monoclonal/polyclonal), and conjugation tags (e.g., HRP, FITC). Proper validation ensures reliable results, aiding studies on nucleoside metabolism, drug delivery, and therapeutic targeting of SLC29A1 in diseases like cancer or ischemia.
×
